Opinion|Videos|August 20, 2024
Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response
Experts discuss the results of the CORE-001 Trial.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- In the CORE-001 trial, what were the results for the primary endpoint of complete response at 24 months as well as the secondary endpoint of duration of response? What is notable about these results?
- How do these results compare to those associated with other FDA-approved therapies and other investigational drugs?
- What was the overall cystectomy-free survival rate, and what was this rate among patients who experienced a complete response?
- Were there other notable efficacy outcomes?
Advertisement
Related to this article
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Systemic therapy now anchors MIBC care and expands bladder preservation options, according to Joshua J. Meeks, MD, PhD.
BCG optimization should precede checkpoint inhibitor intensification in BCG-naive high-risk NMIBC, according to Tom Jayram, MD.
The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
3
FAQ: ASTRO guideline on hypofractionated radiation therapy for localized prostate cancer
4
Nogapendekin alfa inbakicept plus BCG meets primary end point in BCG-naïve NMIBC
5